GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Shiller PE Ratio

AIM ImmunoTech (AIM ImmunoTech) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AIM ImmunoTech Shiller PE Ratio Historical Data

The historical data trend for AIM ImmunoTech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Shiller PE Ratio Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's Shiller PE Ratio

For the Biotechnology subindustry, AIM ImmunoTech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Shiller PE Ratio falls into.



AIM ImmunoTech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AIM ImmunoTech's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, AIM ImmunoTech's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.26/129.4194*129.4194
=-0.260

Current CPI (Dec. 2023) = 129.4194.

AIM ImmunoTech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -10.560 99.695 -13.709
201406 -15.840 100.560 -20.386
201409 -10.560 100.428 -13.608
201412 -11.880 99.070 -15.519
201503 -10.560 99.621 -13.719
201506 -10.560 100.684 -13.574
201509 -7.920 100.392 -10.210
201512 -6.600 99.792 -8.559
201603 -4.400 100.470 -5.668
201606 -2.640 101.688 -3.360
201609 -5.720 101.861 -7.268
201612 -1.760 101.863 -2.236
201703 -4.840 102.862 -6.090
201706 -3.520 103.349 -4.408
201709 -1.760 104.136 -2.187
201712 -2.640 104.011 -3.285
201803 -3.080 105.290 -3.786
201806 -2.380 106.317 -2.897
201809 -2.870 106.507 -3.487
201812 -1.320 105.998 -1.612
201903 -2.910 107.251 -3.512
201906 -1.070 108.070 -1.281
201909 -1.130 108.329 -1.350
201912 -0.102 108.420 -0.122
202003 -0.220 108.902 -0.261
202006 -0.110 108.767 -0.131
202009 -0.080 109.815 -0.094
202012 -0.090 109.897 -0.106
202103 -0.080 111.754 -0.093
202106 -0.120 114.631 -0.135
202109 -0.080 115.734 -0.089
202112 -0.120 117.630 -0.132
202203 -0.080 121.301 -0.085
202206 -0.100 125.017 -0.104
202209 -0.130 125.227 -0.134
202212 -0.090 125.222 -0.093
202303 -0.080 127.348 -0.081
202306 -0.100 128.729 -0.101
202309 -0.160 129.860 -0.159
202312 -0.260 129.419 -0.260

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AIM ImmunoTech  (AMEX:AIM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AIM ImmunoTech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (AIM ImmunoTech) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976

AIM ImmunoTech (AIM ImmunoTech) Headlines

From GuruFocus